American Urological Association - APN/PA Spotlight on Female Sexual Dysfunction

advertisement

Home Education Educational Programs APN/PA/Allied Education Spotlight on Female Sexual Dysfunction

APN/PA Spotlight on Female Sexual Dysfunction

The prevalence of Female Sexual Dysfunction (FSD) a disease encompassing sexual desire and arousal disorders, orgasmic disorders, and sexual pain disorders, is a complex and important clinical issue. In the National Health and Social Life Survey, 43% of women reported some degree of sexual difficulty. There is a disparity in the treatment of sexual dysfunction between women and men that is now correcting. Urologists have become experienced with an emerging trend of male sexual dysfunction, which has been widely accommodated in the pharmaceutical and urological communities. Due to the multifactorial nature of Female Sexual Dysfunction, no FDA approved single-agent therapy has been proven to effectively treat this complex disorder.

As PAs and ANPs are medical professionals whose work often emphasizes responsible history taking, patient education (with regards to medication and treatment options and side effects) and as patient advocates and liaisons to their physician partners, they can become a key asset in bridging this practice gap nationwide. The need for increased didactic knowledge, as well as maintaining the competency level of the female uro-gynecological physical examination, will be key elements in desired outcomes.

Learning Objectives

After attending this activity, participants should be able to:

  1. Describe a proactive, professional, and considerate sexual health history and review of systems in the female patient with sexual dysfunction
  2. Recognize physical exam signs and symptoms of Female Sexual Dysfunction
  3. Properly outline and assign treatments options based on the specific etiology of the Female Sexual Dysfunction
  4. Discuss the utility of ancillary clinical therapies and healthcare providers for women with sexual dysfunction (psychological counseling, pelvic floor PT, surgeons, endocrinologists, gynecologists)
  5. Outline methods to improve female sexual health, assist in the continuity of care, and carry out long-term follow-up planning

This educational activity is a member benefit; however, it is available to non-members upon purchase.

Target Audience

  • Physician Assistants
  • Advanced Practice Nurses
  • Registered Nurses

Method of Participation

Learners will participate in this interactive online educational activity by reading through slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 2.0 hour

Release Date: February, 2015

Expiration Date: February, 2018

A PC-compatible computer running Windows XP or a Macintosh computer running OS X 10.4 or later. Internet access. Adobe Acrobat Reader 9 or newer.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Faculty

The content of this enduring material was developed by John P. Mulhall, MD and Thomas P. McBride, PA-C with contributions from Stanley E. Althof, PhD and Michael L. Krychman, MD.

Faculty Disclosures

Stanley E. Althof, PhD: Lilly\ICOS: Consultant or Advisor; Palitan: Consultant or Advisor, Scientific Study or Trial; Abbott: Consultant or Advisor; Bayer: Consultant or Advisor; Allergan: Consultant or Advisor, Scientific Study or Trial; Plethora: Consultant or Advisor; Sprout: Consultant or Advisor; Trimel: Scientific Study or Trial; Ixchelsis: Consultant or Advisor

Michael L. Krychman, MD: Triton Pharmaceutical Canada: Consultant or Advisor; Salix: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Thomas P. McBride, PA-C: Adirondack Society of Physician Assistants: Leadership Position, Meeting Participant or Lecturer; Dendreon Corporation: Investment Interest; SeekingAlpha.com: Health Publishing

John P. Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Scientific Study or Trial; Vivus: Consultant or Advisor, Scientific Study or Trial; Nexmed: Consultant or Advisor; Absorption Pharmaceuticals: Consultant or Advisor; AMS: Consultant or Advisor, Scientific Study or Trial; Meda: Consultant or Advisor; Lilly: Consultant or Advisor; Alliance for Fertility Preservation: Leadership Position

Planner Disclosures

Education Council

Christopher Lee Amling, MD: Janssen: Meeting Participant or Lecturer

Gopal Badlani, MD: Lithotripsy Group: Piedmont stone & Physician Discovery: Investment Interest; Society of University Urologist: Leadership Position; NIDDK: Leadership Position

Timothy Charles Brand, MD: Nothing to disclose

Peter Robert Carroll, MD: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Abbott Pharmaceuticals: Scientific Study or Trial; AUA Update: Leadership Position; Astra Zeneca: Meeting Participant or Lecturer; Genome Dx: Consultant or Advisor; Intuitive: Meeting Participant or Lecturer; Genomic Health: Consultant or Advisor; Takeda Pharmaceutical Company: Meeting Participant or Lecturer; Teva Pharmaceutical Industries: Meeting Participant or Lecturer; Janssen Pharmaceutical Companies: Meeting Participant or Lecturer; Intuitive Surgical Inc.: Meeting Participant or Lecturer

Sam S. Chang, MD: Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor; Dendreon: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; Cepheid: Scientific Study or Trial

Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest

Bruce R. Gilbert, MD, PhD: Bayer Healthcare Pharmaceuticals Inc.: Scientific Study or Trial; Auxilium: Scientific Study or Trial; Clarus Pharmaceutcals: Scientific Study or Trial; Eli Lilly: Scientific Study or Trial; Warner Chilcott: Scientific Study or Trial

Christina Hernandez (AUA Staff): Nothing to disclose

Douglas A. Husmann, MD: Nothing to disclose

Wes Kassouf, MD: Nothing to disclose

Louis Koncz, PA-C: Nothing to discloseS

Cheryl Taylore Lee, MD: Adolor: Scientific Study or Trial; Tengion, Inc.: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Photocure: Consultant or Advisor; CVI: Consultant or Advisor

Thomas Sean Lendvay, MD: Spi Surgical Inc.: Consultant or Advisor, Owner, Product Development; MIMIC Technologies Inc.: Other

Vinata B. Lokeshwar, PhD: Nothing to disclose

Elspeth Marguerita McDougall, MD: Nothing to disclose

John Patrick Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Scientific Study or Trial; Vivus: Consultant or Advisor, Scientific Study or Trial; Nexmed: Consultant or Advisor; Absorption Pharmaceuticals: Consultant or Advisor; AMS: Consultant or Advisor, Scientific Study or Trial; Meda: Consultant or Advisor; Lilly: Consultant or Advisor; Alliance for Fertility Preservation: Leadership Position

J. Kellogg Parsons, MD: AMS: Meeting Participant or Lecturer; Sophiris: Consultant or Advisor; Watson: Consultant or Advisor

Lee Richstone, MD: Wundercare LLC: Consultant or Advisor

Marianne D. Sadar, PhD: ESSA Pharma Inc.: Leadership Position, Consultant or Advisor, Investment Interest

Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Photocure: Scientific Study or Trial; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer

Sheila Stark, PhD (AUA Staff): Nothing to disclose

William Donald Steers, MD: National Institutes of Health: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Scientific Study or Trial; New England Research Institute (NERI): Consultant or Advisor, Scientific Study or Trial

Chandru P. Sundaram, MD: Cook Medical Inc.: Scientific Study or Trial; North Central Section of the AUA: Leadership Position; Journal of Endourology and Videourology: Leadership Position; Society of Urological Robotic Surgeons: Leadership Position

Ashutosh Kumar Tewari, MD: Intuitive Surgical: Scientific Study or Trial; Kalyani Prostate Cancer Institute: Leadership Position; Global Prostate Cancer Foundation: Leadership Position; Peter Georgescu Foundation Award: Leadership Position; Chris Lange Foundation: Other; Peter Kalikow Foundation: Other; Craig Effron Foundation: Other; Tim O'Neill Foundation: Other; Patent for a Catheter-less device and approach: Other; NIH RO1 Funding-PI: Other

Paul Jacob Turek, MD: MandalMed: Leadership Position; Medical Board of California: Consultant or Advisor; BioQuiddity, Inc.: Consultant or Advisor, Investment Interest; HealthLoop.com: Consultant or Advisor, Investment Interest; Doximity, Inc.: Consultant or Advisor, Investment Interest; Fertility Planit, Inc.: Consultant or Advisor, Investment Interest

Alan J. Wein, MD, PHD (HON): Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; Ferring Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer; Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Merck: Consultant or Advisor; opko: Consultant or Advisor; theravida: Consultant or Advisor

APN/PA Education Committee

Jeffrey A. Albaugh, PhD, APRN-BC, CUCNS: Sexual Medicine Society of North America: Leadership Position, Meeting Participant or Lecturer; Society of Urologic Nurses & Associates: Leadership Position, Meeting Participant or Lecturer; Prostate Net: Meeting Participant or Lecturer; Jannetti Publications Inc.: Other; Actient Pharmaceuticals LLC: Consultant or Advisor, Meeting Participant or Lecturer; Astellas Pharma: Consultant or Advisor; Medivation: Consultant or Advisor

Roxelyn Baumgartner, RN, APN-BC: Nothing to disclose

Ashleigh Decker, PA-C: Nothing to disclose

Todd James Doran, MS, PA-C: Urological Association of Physician Assistants: Leadership Position; Physician Assistant Education Association: Leadership Position

Susan M. Flick, CNP: Pfizer: Other

Peggy Francis, DNP, RN, MSN, CS, FNP-BC, CUNP: Warner Chilcott: Meeting Participant or Lecturer

Gina Fries, RPA-C: Astellas Pharma US: Scientific Study or Trial

Raymond Matthew Galocy, ANP-C: Nothing to disclose

Michele Huebner, PA-C: Urological Association of Physician Assistants: Leadership Position

Louis Koncz, PA-C: Nothing to disclose

Ralph Raphael Madeb, MD: Nothing to disclose

Thomas P. McBride, PA-C: Adirondack Society of Physician Assistants: Leadership Position, Meeting Participant or Lecturer; Dendreon Corporation: Investment Interest; SeekingAlpha.com: Health Publishing

Heather Schultz, NP: Nothing to disclose

Allen D. Seftel, MD: Auxilium: Consultant or Advisor, Scientific Study or Trial; Journal of Urology: Leadership Position; Abbott: Consultant or Advisor; Lilly: Consultant or Advisor, Scientific Study or Trial; Journal of Sexual Medicine: Leadership Position; American Geriatrics Society: Leadership Position; Urology Care Foundation: Leadership Position; Mid-Atlantic Section of AUA: Leadership Position; AUA NPP committee: Leadership Position; International Journal of Impotence Research: Leadership Position; Patient Pocket, LLC: Owner, Product Development

Meredith Vaccaro (AUA Staff): Nothing to disclose

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the product prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Confidentiality Statement

Contact Information

American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: cme@AUAnet.org

Advertisement

Advertisement

Additional Information